Eli Lilly's COVID-19 antibody sales crater as variants, vaccines take a toll Alnylam scraps COVID-19 antiviral citing effective vaccines, alternative treatments Kaiser Permanente requiring all 240K employees, physicians to be fully vaccinated against COVID-19 CytoDyn catches SEC, DOJ scrutiny over public claims about COVID-19 drug's viability With $3.2B, Sanofi takes in mRNA partner Translate Bio in buyout deal UPDATED Coronavirus tracker: Health policy expert calls for wider use of N95s, simpler masking recommendations COVID-19 tracker: U.S. donates over 110M doses so far; Alnylam, Vir ditch antiviral due to vaccines, other drugs Featured Story | By Noah Higgins-Dunn Eli Lilly's COVID-19 antibody sales plummeted as virus variants and greater vaccine access weighed on the company's pandemic prospects. read more |
| |
|---|
|
Top Stories By Kyle LaHucik The pharma said it was ending ALN-COV, its RNAi antiviral being developed for the treatment of SARS-CoV-2, because of the number of effective vaccines and alternative treatments available. Alnylam and partner Vir Biotechnology had said they would start testing patients by the end of last year. read more By Dave Muoio With its Sept. 30 cutoff, Kaiser Permanente is now the largest health system to mandate a COVID-19 vaccine among employees. read more By Annalee Armstrong The blows keep coming for CytoDyn. After the FDA blasted the company for pumping up their unapproved and unproven COVID-19 therapeutic, the Department of Justice and the Securities and Exchange Commission is now subpoenaing the company and its executives. Two investigations were disclosed in an SEC filing dated July 30. read more By Nick Paul Taylor After being left out of the COVID-19 vaccine race despite having an early investment in mRNA technology, which would go on to give the world two vaccines in record-breaking time, Sanofi has struck a deal to buy its mRNA partner Translate Bio in a $3.2 billion deal. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The U.S. has donated over 110 million vaccine doses to more than 60 countries, and the Biden administration said that's just the start. Alnylam and Vir Biotechnology are ditching their COVID-19 antiviral, citing the availability of highly effective vaccines and alternative treatments. And more headlines. read more |
